Stocktoria
Opus Genetics, Inc. IRD
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-11-30
Opus Genetics, Inc. statistics & valuation
Market cap$330.3M
P / S23.3×
P / B21.5×
Net margin-349.3%
Net cash$44.0M
Enterprise value USD$286.3M
Earnings yield EBIT/EV-13.5%
Return on capital-90.9%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -271.9% | -564.7% | -55.5% | 45.7% | -3854.8% | — | -139.8% | — | — | — |
| Net margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | — | -205.6% | — | — | — |
| FCF margin | — | — | — | — | — | — | -120.6% | — | — | — |
| Return on assets | -98.7% | -156.1% | -18.5% | 36.5% | -217.4% | -139.2% | -345.8% | -89.6% | -89.4% | -44.2% |
| Return on equity | -323.1% | -855.6% | -20.0% | 38.7% | -255.1% | 182.8% | 81.6% | 845.7% | -150.8% | -54.6% |
| Debt / equity | 0.07× | 0.00× | — | — | — | — | — | — | — | — |
| Current ratio | 6.43 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 | 5.04 | — | — |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.